News Focus
News Focus
icon url

DewDiligence

04/20/16 2:29 PM

#12460 RE: DewDiligence #12459

ABT raised 2016 non-GAAP EPS guidance to $2.14-2.24 (from old range of $2.10-2.20) based on a solid 1Q16, especially in emerging markets:

http://finance.yahoo.com/news/abbott-reports-first-quarter-2016-114500807.html

Sales of branded-generic drugs in India (ABT’s largest market) were +11% YoY in constant currency.
icon url

DewDiligence

07/27/16 3:59 PM

#12938 RE: DewDiligence #12459

ABT might be off the hook for ALR buyout after the latest news:

icon url

DewDiligence

12/07/16 11:30 AM

#13746 RE: DewDiligence #12459

ABT formally seeks to kill ALR acquisition:

http://abbott.mediaroom.com/2016-12-07-Abbott-Seeks-to-Terminate-Alere-Acquisition

Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value following the merger agreement.

In the 10 months following the Jan. 30, 2016, signing of the agreement, Alere has suffered a series of damaging business developments, including the government eliminating the billing privileges of a substantial Alere division, the permanent recall of an important product platform, multiple new government subpoenas, including two new criminal subpoenas, and a five-month delay in filing its 10K coupled with admissions of internal control failures requiring restatement of its 2013-2015 financials.

"Alere is no longer the company Abbott agreed to buy 10 months ago," said Scott Stoffel, divisional vice president of external communications, Abbott. "These numerous negative developments are unprecedented and are not isolated incidents brought on by chance. We have attempted to secure details and information to assess these issues for months, and Alere has blocked every attempt. This damage to Alere's business can only be the result of a systemic failure of internal controls, which combined with the lack of transparency, led us to filing this complaint."

Under terms of the merger agreement, Abbott may terminate the transaction if adverse events materially change Alere's long-term prospects. Abbott filed its complaint seeking termination in the Delaware Court of Chancery, citing these events among others as material adverse events.

As an ABT long, I hope the Chancery Court grants ABT’s complaint.